Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Prostate biopsy guided by PSMA PET/CT
The First People's Hospital of Lianyungang
PSMA PET/CT
1 trial -
Protein supplementation
Hospital Authority, Hong Kong
Hip Fractures
1 trial -
Protocol-based management of perioperative antithrombotic therapy
The First People's Hospital of Lianyungang
Antithrombotic Therapy
1 trial -
Protocol-based management of perioperative antithrombotic therapy
Peking University Third Hospital
Antithrombotic Therapy
1 trial -
Pueraria lobata radix
The First People's Hospital of Lianyungang
Type 2 Diabetes Mellitus
1 trial -
Pulsed dye laser (PDL)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Port Wine Stain
1 trial -
QFR
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Artery Disease
1 trial -
Qingre Huashi Granules combined the modified dual therapy
The First People's Hospital of Lianyungang
Helicobacter Pylori Infection
1 trial -
R-CDOP
The First People's Hospital of Lianyungang
Diffuse Large B Cell Lymphoma
1 trial -
RB001
The First People's Hospital of Lianyungang
Phelan-McDermid Syndrome
1 trial -
REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]
Hospital Authority, Hong Kong
Hemodynamic Instability
1 trial -
Rabeprazole 20mg twice daily
Hospital Authority, Hong Kong
Chest Pain
1 trial -
Raman spectrum
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer
1 trial -
Recombinant COVID-19 Vaccine (Sf9 Cell)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
COVID-19
1 trial -
Reduction CTVp1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Regional lymph node radiotherapy (RNI) including the axilla
The First People's Hospital of Lianyungang
Axillary Lymph Node Dissection
1 trial -
Regorafenib and Sintilimab in combination with electroacupuncture
The First People's Hospital of Lianyungang
Colorectal Cancer Metastatic
1 trial -
Remimazolam
The First People's Hospital of Lianyungang
Sedation and Analgesia
1 trial -
Remimazolam Tosilate
The First People's Hospital of Lianyungang
Frailty
1 trial -
Remimazolam besylate
The First People's Hospital of Lianyungang
Remimazolam
1 trial -
Respiratory monitoring
The First People's Hospital of Lianyungang
Post-Op Complication
1 trial -
Rifaximin
The First People's Hospital of Lianyungang
Bacterial Overgrowth Syndrome Small Bowel
1 trial -
Ringer's solution acetate
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cholecystolithiasis and Thyroid Nodule
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral T-Cell Lymphoma, Not Otherwise Specified
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources